Literature DB >> 8665520

DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines.

K Mikami1, M Naito, A Tomida, M Yamada, T Sirakusa, T Tsuruo.   

Abstract

Mitomycin C (MMC), a known cytotoxic agent, requires cellular enzyme-mediated activation for effective antitumor activity. To study the bioreductive enzymes responsible for MMC activation in tumor cells, we examined the enzyme activities of DT-diaphorase (DTD) and NADPH:cytochrome P-450 reductase in 13 colon and gastric carcinoma cell lines and then compared these activities to the respective cellular MMC sensitivity. We found that cell lines with nonexistent or marginal DTD activity, such as St-4 and MKN7, showed resistance to MMC, in comparison to cell lines with DTD activity ranging from 210 to 1420 nmol/min/mg protein. No correlation was found between NADPH:cytochrome P-450 reductase activity and MMC sensitivity in these cell lines. To confirm the role of DTD in cellular MMC sensitivity, we constructed an expression vector containing NQO1, a gene that codes for DTD, and transfected the vector into St-4 cells expressing no DTD activity. Several transfectant clones with DTD activity from 144 to 2085 nmol/min/mg protein were obtained. All of the transfectants showed 5-10-fold higher sensitivity to MMC compared to the parental St-4 cells. Consistent with the MMC sensitivity, we also found that MMC-DNA adduct was formed more extensively in the NQO1 transfectants than in the St-4 cells. These results indicate that DTD activity is required for effective cytotoxicity of MMC in colon and gastric carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8665520

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Distinct roles of cytochrome P450 reductase in mitomycin C redox cycling and cytotoxicity.

Authors:  Yun Wang; Joshua P Gray; Vladimir Mishin; Diane E Heck; Debra L Laskin; Jeffrey D Laskin
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

2.  Characterization of the threshold for NAD(P)H:quinone oxidoreductase activity in intact sulforaphane-treated pulmonary arterial endothelial cells.

Authors:  Robert D Bongard; Gary S Krenz; Adam J Gastonguay; Carol L Williams; Brian J Lindemer; Marilyn P Merker
Journal:  Free Radic Biol Med       Date:  2011-01-14       Impact factor: 7.376

Review 3.  NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.

Authors:  David Siegel; Chao Yan; David Ross
Journal:  Biochem Pharmacol       Date:  2011-12-24       Impact factor: 6.100

4.  Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents.

Authors:  G P Doherty; M K Leith; X Wang; T J Curphey; A Begleiter
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

5.  Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer.

Authors:  D J Propper; N C Levitt; K O'Byrne; J P Braybrooke; D C Talbot; T S Ganesan; C H Thompson; B Rajagopalan; T J Littlewood; R M Dixon; A L Harris
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

6.  Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor.

Authors:  D Jamieson; A T Y Tung; R J Knox; A V Boddy
Journal:  Br J Cancer       Date:  2006-10-10       Impact factor: 7.640

7.  Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase.

Authors:  X Wang; G P Doherty; M K Leith; T J Curphey; A Begleiter
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

8.  The two common polymorphic forms of human NRH-quinone oxidoreductase 2 (NQO2) have different biochemical properties.

Authors:  Clare F Megarity; James R E Gill; M Clare Caraher; Ian J Stratford; Karen A Nolan; David J Timson
Journal:  FEBS Lett       Date:  2014-03-12       Impact factor: 4.124

Review 9.  Implications of NQO1 in cancer therapy.

Authors:  Eun-Taex Oh; Heon Joo Park
Journal:  BMB Rep       Date:  2015-11       Impact factor: 4.778

10.  NQO1 inhibits proteasome-mediated degradation of HIF-1α.

Authors:  Eun-Taex Oh; Jung-Whan Kim; Joon Mee Kim; Soo Jung Kim; Jae-Seon Lee; Soon-Sun Hong; Justin Goodwin; Robin J Ruthenborg; Myung Gu Jung; Hae-June Lee; Chul-Ho Lee; Eun Sung Park; Chulhee Kim; Heon Joo Park
Journal:  Nat Commun       Date:  2016-12-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.